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Introduction: Because small-cell lung carcinomas (SCLC) are sel-
dom resected, human materials for study are limited. Thus, geneti-
cally engineered mouse models (GEMMs) for SCLC and other 
high-grade lung neuroendocrine (NE) carcinomas are crucial for 
translational research.
Methods: The pathologies of five GEMMs were studied in detail 
and consensus diagnoses reached by four lung cancer pathology 
experts. Hematoxylin and Eosin and immunostained slides of over 
100 mice were obtained from the originating and other laboratories 
and digitalized. The GEMMs included the original Rb/p53 double 
knockout (Berns Laboratory) and triple knockouts from the Sage, 
MacPherson, and Jacks laboratories (double knockout model plus 
loss of p130 [Sage laboratory] or loss of Pten [MacPherson and Jacks 
laboratories]). In addition, a GEMM with constitutive co-expression 
of SV40 large T antigen and Ascl1 under the Scgb1a1 promoter from 
the Linnoila laboratory were included.
Results: The lung tumors in all of the models had common as well as 
distinct pathological features. All three conditional knockout models 
resulted in multiple pulmonary tumors arising mainly from the central 
compartment (large bronchi) with foci of in situ carcinoma and NE 
cell hyperplasia. They consisted of inter- and intra-tumor mixtures 
of SCLC and large-cell NE cell carcinoma in varying proportions. 
Occasional adeno- or large-cell carcinomas were also seen. Extensive 
vascular and lymphatic invasion and metastases to the mediastinum 
and liver were noted, mainly of SCLC histology. In the Rb/p53/Pten 
triple knockout model from the MacPherson and Jacks laboratories 
and in the constitutive SV40/T antigen model many peripherally aris-
ing non–small-cell lung carcinoma tumors having varying degrees of 
NE marker expression were present (non–small-cell lung carcinoma-
NE tumors). The resultant histological phenotypes were influenced 
by the introduction of specific genetic alterations, by inactivation of 
one or both alleles of specific genes, by time from Cre activation and 
by targeting of lung cells or NE cell subpopulations.
Conclusion: The five GEMM models studied are representative for 
the entire spectrum of human high-grade NE carcinomas and are also 
useful for the study of multistage pathogenesis and the metastatic 
properties of these tumors. They represent one of the most advanced 
forms of currently available GEMM models for the study of human 
cancer.
Key Words: Neuroendocrine carcinomas, Small-cell lung carci-
noma, Lung carcinoma, Non–small-cell lung cancer, Genetically 
engineered mouse models, Pathology.
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For a number of clinical, therapeutic, pathological, and bio-logical reasons, small-cell carcinoma of the lung (SCLC) 
is regarded as an entity distinct from the more common non–
small-cell lung carcinomas (NSCLC).1,2 SCLC is neuroendo-
crine (NE) tumor and it is the most common and aggressive 
subtype within the spectrum of NE lung tumors. NE tumors 
of the lung are a distinct subset of tumors, which share mor-
phologic, ultrastructural, immunohistochemical, and molecu-
lar characteristics although these tumors are classified into 
different morphologic categories within the World Health 
Organization classification.3,4 Pulmonary NE tumors may be 
divided into two categories: (1) high-grade NE carcinomas 
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consisting of SCLC and large-cell NE carcinomas (LCNEC) 
and (2) low-grade NE tumors consisting of the carcinoid 
tumors, typical and atypical.5 High-grade NE lung carcino-
mas are characterized by strong association with tobacco 
usage, high mitotic and proliferative indices, initial response 
to chemotherapy, widespread metastases, almost universal 
inactivation of the TP53 and RB1 genes, and other character-
istic molecular alterations. Whether all NE tumors arise from 
respiratory tract NE cells, from less differentiated multipo-
tent cells, or cells committed to other lineages is disputed.6,7 
Although all pulmonary NE tumors may originate from the 
same pulmonary precursor cells, precursor lesions have not 
been convincingly identified for high-grade NE carcinomas.8 
Pulmonary NE cell hyperplasia has been observed in asso-
ciation with carcinoids, but no clear association is recognized 
with other lung cancers including SCLC.9,10
Multiple potential targets for individualized therapy 
have been identified in SCLC cells.11,12 However, despite 
several clinical trials, effective targeted therapies for SCLC 
are not currently available.13 Because curative intent resec-
tions are seldom performed for SCLC, there is a paucity of 
tumor materials for the performance of translational research. 
Biological and preclinical studies of SCLC largely depend on 
the availability of modest sized banks of human cell lines.14 
Thus, the introduction of a genetically engineered mouse 
model15 resulting from the somatic inactivation of the Tp53 
and Rb1 genes represented an important step.2 These mice 
developed aggressive NE lung cancers, termed SCLC, which 
gave rise to extrapulmonary metastases and required bi-allelic 
inactivation of both genes. A reported preinvasive feature was 
the presence of hyperplastic and dysplastic foci and nodules, 
particularly in the larger airways. However, the latent period 
for tumor formation was relatively long (7–12 months). 
Later, Schaffer et al.16 reported that the additional conditional 
loss of p130, a cell cycle inhibitor in the Rb1 gene family, 
shortened the latent time in the Rb/p53/p130 triple-knockout 
mouse model. The histopathology of these metastatic mouse 
tumors was also reported to closely resemble human SCLC. 
More recently, another triple knockout model (with the addi-
tional conditional inactivation of the Pten gene in the Rb/Tp53 
floxed model) has been described.17 Heterogeneous inactiva-
tion of the Pten gene resulted in SCLC like tumors after a 
shorter latent period, but also in adenocarcinomas with vary-
ing degrees of NE cell differentiation (NSCLC-NE tumors). 
Homozygous inactivation of Pten resulted in NSCLC carcino-
mas with varying degrees of NE cell differentiation. Another 
variation of the Rb/p53/Pten triple knockout model has been 
described by McFadden et al.18 A further complicating factor 
of the classification of NE carcinomas is that some otherwise 
typical appearing human NSCLC tumors, usually adenocar-
cinomas, express much or all of the NE cell program—so 
called NSCLC with NE features (NSCLC-NE). These tumors 
remain largely unstudied with differing views on incidence 
and therapeutic options.19–24 However, microarray expression 
profiling identifies a subgroup of human lung adenocarcino-
mas that express NE cell features, confirming the presence 
of NSCLC-NE as a subset of NSCLC.25,26 Congress passed 
into law the Recalcitrant Cancer Research Act in 2013, calling 
on the National Cancer Institute (NCI) “to develop scientific 
frameworks that will help provide the strategic direction and 
guidance needed to make true progress against recalcitrant 
cancers,” defined as those with a 5-year relative survival rate 
below 50%. Following a workshop held in Bethesda, MD 
in 2013, a report on “The Scientific Framework for Small 
Cell Lung Cancer” was issued (http://www.lungcanceral-
liance.org/News/SCLC%20Congressional%20Response%20
6-30-14%20FINAL%20with%20appendices.pdf). One of the 
priorities identified in the report was the development of bet-
ter models for SCLC including genetically engineered mouse 
models (GEMMs). As described below, five GEMM models 
for NE lung carcinomas have been described, and more are 
under development. However, descriptions of the detailed 
pathology of most of these models are lacking. Recently, we 
(AFG and EB) had the opportunity to review the pathology 
of the GEMMs propagated at our respective institutions (UT 
Southwestern Medical Center and Institut Albert Bonniot). 
We found similarities and differences between the histological 
appearances of the mouse models and human SCLC, and also 
between the different mouse models. We undertook detailed 
analyses of the pathology of the currently described NE mouse 
models and their preinvasive changes, and invited the senior 
initiators of the models (AB, JS, DM, IL, and TJ) to collabo-
rate with us and submit pathological materials of the GEMMs 
from their respective laboratories for pathological examina-
tion. The primary purpose of the study was to determine the 
suitability of the GEMMs as models for the study of human 
SCLC and other NE carcinomas.
MATERIALS AND METHODS
Genetically Engineered Mouse Models
Five GEMMs for NE lung tumors were obtained from 
seven independent laboratories, the originating laboratory, 
as well as from multiple sources for some models (Table 1). 
These models have been described previously, and details are 
available from the cited references. For the conditional mod-
els, tumors were initiated by adenoviral delivery of Cre.27
Pathology Examination
Tissues from over 120 mice were examined, over 80 from 
the Rb/p53 double knockout model, and five to 15 each from 
the other four models. Mice were sacrificed either when symp-
tomatic or at defined intervals after Cre activation. Lungs and 
other tissues (liver, mediastinum, regional lymph nodes) were 
fixed in neutral buffered formalin, paraffin embedded and 5 
μ H. & E. stained sections were prepared. For representative 
cases immunostains for NE cell markers (Ascl1, ChgA, Cgrp, 
and Syn) were performed on corresponding sections. NKX2-1 
staining, a marker for both adenocarcinoma and NE lung can-
cers, was available for some tumors. Entire slides were digitally 
scanned at high (40×) resolution using the NanoZoomer 2.0 HT 
Digital Pathology System (Hamamatsu Photonics, Hamamatsu 
City, JP) and examined using the manufacturer’s software. One 
pathologist (AFG) examined all of the scanned images in detail 
and captured multiple representative images. These were dis-
tributed to the other three pathologists (EB, WDT, and IL) and 
consensus diagnoses were reached about each model.
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Pathologic Criteria for Diagnosis
For diagnosis, we used standard definitions as stated by 
the World Health Organization classification of tumors of the 
lung:3,4 (1) SCLC: A NE carcinoma having cells of a small size, 
with scant cytoplasm, nuclei with finely granular nuclear chro-
matin, inconspicuous nucleoli, high mitotic rate, frequent necro-
sis often covering large zones (“geographic necrosis”). Another 
criterion we used was the presence of the Azzopardi effect in 
ischemic areas, a feature present in about 30% of human SCLC 
tumors.28 This feature, highly characteristic of SCLC, represents 
deposition of basophilic DNA-containing material on blood ves-
sel walls resulting from release of nucleic acids in large amounts 
from degenerating cellular neoplastic tissues. (2) Large-cell NE 
carcinoma (LCNEC): A tumor with a NE morphology (organ-
oid nesting, palisading, rosettes, trabeculae), high mitotic rate, 
frequent area of necrosis, often geographic, cytologic features 
of a NSCLC (large cell size, low nuclear to cytoplasmic ratio, 
vesicular, coarse or fine chromatin, and/or frequent nucleoli). 
Some tumors have fine nuclear chromatin and lack nucleoli, but 
qualify as NSCLC because of large cell size and abundant cyto-
plasm.10 (3) NSCLC-NE. These are defined as otherwise typical 
NSCLC tumors (often adenocarcinomas or large-cell carcino-
mas) expressing one or more NE cell properties, but lacking the 
typical morphological features of NE carcinomas (see above). 
Demonstration of NE cell properties by positive immunostain-
ing for one or more NE markers (other than neuron-specific eno-
lase) and/or presence of cytoplasmic NE granules by electron 
microscopy. These tumors remain largely unstudied with differ-
ing views on incidence and therapeutic options.22–24,29
RESULTS
A brief overview of the major pathological changes 
observed in the various GEMMs is presented in Table 2.
Pathology of Rb/p53 Double Knockout and 
Rb/p53/p130 Triple Knockout GEMMs
These represent the original Rb/p53 double knockout 
established in the Berns laboratory in 2003. In an effort to 
shorten the lengthy latency time, the Sage laboratory created 
the first of the triple knockouts in 2010. Both of these models 
gave rise to central tumors arising from noninvasive lesions 
originating in the large bronchi, although occasional tumors 
appear to have arisen in the peripheral lung from respiratory 
bronchioles or alveolar ducts. Most of the preinvasive lesions 
consisted of cells having similar morphology to the accom-
panying invasive component (see below), and were regarded 
as carcinoma in situ lesions. The distinction between SCLC 
(Figs. 1 and 2) and LCNEC (Fig. 3) was more difficult in the 
in situ lesions, especially small ones. Neuroepithelial bod-
ies (NEB) and foci of NE cell hyperplasia protruding into 
the lumen were occasionally present although most appeared 
independent of the in situ and invasive components. The Rb/
p53 double knockout was the most abundant source of materi-
als for this study, with over 80 affected mice available from 
all five participating laboratories. Irrespective of the labora-
tory source, the pathology of the resultant mouse tumors was 
uniform and virtually identical. Mice were sacrificed 10–15 
months after Cre activation. Mice sacrificed early had mainly 
in situ lesions, while mice sacrificed later had multiple tumors 
occupying up to 60% of the lung volume, with vascular and 
peribronchial invasion and perivascular and peribronchial 
intralymphatic metastases (Fig. 2). They were accompanied 
by extensive mediastinal spread and lymph node and hepatic 
metastases. In some cases, extensive mediastinal involvement 
was noted with only modest intrapulmonary tumor burdens. 
The histology of most of the metastases consisted largely or 
solely of the SCLC cell component (see below). The majority 
TABLE 1.  GEMMs Used in the Study
Identification Laboratory Source
Brief Description of Induced 
Genetic Alteration Target Cells Tissues Examined References
Rb/p53 double knockout Bernsa, Sage, Brambilla, 
Linnoila, Jacks
Conditional inactivation of Rb1  
and Tp53 in lung cells under 
CGRP or CMV promoter
Lung (NE cells) Lung, liver, mediastinum 15
Rb/p53/p130  
Triple knockout
Sage,a Johnson Conditional inactivation of Rb1 
and Tp53 and p130 in lung cells 
under CMV promoter
Lung (nonspecific) Lung, liver mediastinum 16
Rb/p53/Pten triple 
knockoutPtenLox/+
MacPhersona Conditional inactivation of Rb1, 
Tp53 and Ptenlox/+ in lung cells 
under CMV promoter
Lung (nonspecific) Lung, liver, mediastinum 17
Rb/p53/Pten triple 
knockoutPtenLox/lox
MacPhersona Conditional inactivation of Rb1, 
Tp53 and Ptenlox/lox in lung cells 
under CMV promoter
Lung (nonspecific) Lung, liver, mediastinum 17
Rb/p53/Pten triple 
knockoutPtenLox/lox
Jacksa Conditional inactivation of Rb1, 
Tp53 and Ptenlox/lox in lung cells 
under CGRP promoter
Lung (NE cells) Lung, liver 18
CC10-SV40Tag-ASCL1 Linnoilaa Constitutive expression of human 
ASCL1 in combination with 
SV40 Tag under Scgb1a1  
(CC10) promoter in lung cells
Lung (peripheral epithelium) Lung 32
aLaboratory responsible for developing the original model.
GEMM, genetically engineered mouse model; NE, neuroendocrine; Tag, T antigen.
556 Copyright © 2015 by the International Association for the Study of Lung Cancer
Gazdar et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015
of the tumor cells in the Rb/p53 double knockout model were 
very similar to those of human SCLC. The cells formed sheets 
of small cells having high mitotic rates, scant poorly defined 
cytoplasm, nuclei with the presence of small (but distinct) 
nucleoli, areas of geographic necrosis and foci of Azzorpardi 
effect. Minor differences compared with human SCLC were 
the lack of small “salt and pepper” like chromatin granules 
and small but distinct nucleoli in most of the tumor cells. The 
nucleoli in this GEMM were somewhat larger and more dis-
tinct, with some surrounding perinucleolar clearing. A feature 
occupying about 10% of the tumors was the presence of foci 
compatible with LCNEC—the cells were larger, more clearly 
outlined, with larger nuclei and sometimes having prominent 
nucleoli. Features indicative of NE tumors included organ-
oid nests, palisading, trabeculation, and rosette formation. 
The LCNEC foci occurred both as distinct tumor nodules, as 
well as being interspersed with the more typical SCLC com-
ponent. In the mixed foci, transition zones between the two 
histological types were observed. Of interest, the regions with 
Azzopardi effect were limited to the SCLC areas. About 10% 
of the tumors resembled NSCLC, especially adenocarcinoma 
or large-cell carcinoma and they lacked expression of NE cell 
markers. Metastases of the NSCLC tumors were not observed.
The triple Rb/p53/p130 knockout tumors (Fig. 3) from 
the Sage and Johnson laboratories had a shorter latent time 
and the mice were sacrificed electively 5 months post-Cre 
activation or at later times when showing signs of distress. 
Most mice had centrally arising NE tumors, although occa-
sional NSCLC tumors were noted. Mice sacrificed early 
had mainly in situ lesions, whereas mice sacrificed later had 
multiple tumors occupying up to 60% of the lung volume, 
with vascular and lymphatic invasion and perivascular and 
peribronchial intralymphatic metastases. In contrast to the Rb/
p53 double knockout model, the Rb/p53/p130 triple knock-
out tumors had a predominantly LCNEC component when the 
mice were sacrificed early, but the SCLC component became 
more prominent when sacrificed at later time points. In mixed 
histology tumors, the Azzorpardi effects were limited to the 
SCLC component. In some of these mixed tumors, there was 
not a clear distinction between the two NE cell components, 
but a gradual transition from one to the other. However, lym-
phatic, vascular, and hepatic metastases had a predominantly 
SCLC histology, suggesting that this component had a longer 
latent time but also had a greater metastatic potential. As with 
the Rb/p53 double knockout model, occasional foci of NE cell 
hyperplasia or NEBs were noted in bronchi, although there 
was no obvious relation to the in situ or invasive tumors.
Pathology of Rb/p53/Pten Triple 
KnockoutPten GEMMs
The pathology of the tumors, induced by the addition 
of Pten knockout (either Ptenlox/lox or Ptenlox/+)17 to the origi-
nal Rb/p53 double knockout model developed in the Berns 
lab, was more complex than any of the other models included 
in this study. In the MacPherson lab, all lung cells were tar-
geted using intratracheal infection with Ad-CMV-Cre and two 
genotypes were studied—with either one or both Pten alleles 
inactivated by Cre. Mice were sacrificed when symptomatic. 
Tumors developed much faster after adenoviral Cre deliv-
ery with rapid mortality, especially for the Rb/p53/Ptenlox/lox 
mice usually 4–5 months post-Cre and gross metastases were 
not noted. In the Rb/p53/Ptenlox/+ model, dominant tumors 
emerged mostly from mice that got sick 7–9 months post-Cre, 
TABLE 2.  Major Pathological Findings in the GEMMs Studied
Identification Laboratory Source
Time to Sacrifice or 
Symptom Development
Major  
Tumor Type
Minor Tumor 
Type Comments
Rb/p53 double knockout Berns,a Sage, Brambilla, 
Linnoila, Jacks
Elective and symptomatic, 
4–15 months
SCLC LCNEC, 
NSCLC
Mostly late, centrally arising tumors; 
widespread metastases, especially 
after 1 year
Rb/p53/p130 Triple 
knockout
Sage,a Johnson Electively, 3–5 months or 
when symptomatic, 6–8 
months
LCNEC early, 
SCLC later
NSCLC SCLC component predominates in 
metastases
Rb/p53/Pten triple 
knockoutPtenLox/+
MacPhersona Symptomatic, 6–10 months SCLC NSCLC-NE Widespread liver metastases. 
Heterogeneous expression of NE cell 
markers in both phenotypes
Rb/p53/Pten triple 
knockoutPtenLox/lox
MacPhersona Symptomatic, 3–5 months NSCLC-NE NSCLC-NE Liver metastases absent. Heterogeneous 
expression of NE cell markers in all 
phenotypes
Rb/p53/Pten triple 
knockoutPtenLox/lox
Jacksa Symptomatic, 5–8 months LCNEC SCLC, 
NSCLC-NE
Heterogeneous expression of NE 
cell markers in all phenotypes. 
SCLC component predominates in 
metastases
CC10-SV40Tag-ASCL1 Linnoilaa Electively, 2–9 months NSCLC-NE NSCLC Peripherally arising tumors, linear NE 
cell hyperplasia in large airways
Nb. Mice were infected with Adeno-Cre 2–10 weeks after birth. They were sacrificed electively or when symptomatic at the times as indicated. Except for the CC10-SV40Tag-
ASCL1 model, preinvasive lesions and invasive tumors were predominantly central in origin from large airways, although occasional peripherally arising tumors were also noted. In all 
models in which lymph node, mediastinal or liver metastases were observed, the predominant histology of the metastases was SCLC, irrespective of the predominant histology of the 
primary tumors arising in the lung.
NSCLC, non–small-cell lung carcinoma; SCLC, small-cell lung carcinoma; GEMM, genetically engineered mouse model; NE, neuroendocrine; LCNEC, large-cell NE cell 
carcinoma; NSCLC-NE, NSCLC with NE features.
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and about two-thirds had liver metastases. Both of the Rb/
p53/Pten subtype mice had multiple tumors apparently aris-
ing mostly from the central airways (mostly, but also from 
the peripheral airways). The tumors consisted of two major 
subtypes—those resembling SCLC and those with NSCLC 
features, particularly adenocarcinoma. However, the SCLC-
like component was more prominent in the Ptenlox/+ mice. The 
cytological resemblance to human SCLC was not as striking 
as the double Rb/p53 knockout (Berns) model with many cells 
having distinct small nucleoli and defined outer cell borders. 
We refer to these cells as SCLC-like. The NSCLC component 
consisted of adenocarcinomas with acinar and palisading fea-
tures and occasional mucin-like secretory material, both intra- 
and extra-cellular. Multiple large linear, multilayered regions 
of in situ carcinoma were noted. These consisted largely of the 
SCLC cells, although occasionally of the NSCLC component 
or admixtures of the two. By contrast, the in situ lesions in 
the Rb/p53 double and Rb/p53/p130 triple knockout models 
consisted almost entirely of the NE cell component, and were 
smaller and more globular in shape. Foci of hyperplastic basal 
cells or NEBs were rarely identified. Metastases to the medi-
astinal nodes and liver were frequent in the Rb/p53/Ptenlox/+ 
model, and the SCLC-like cell component dominated in the 
metastases. Immunostaining of both morphologic phenotypes 
showed considerable heterogeneity, with some foci of both 
SCLC-like and NSCLC staining uniformly, whereas others 
were negative or were variable in intensity and distribution. 
This heterogeneity extended to in situ and metastatic lesions 
(Fig. 4).
A similar Rb/p53/Pten triple knockout model was devel-
oped in the Jacks laboratory, but using adenoviral Cre vectors 
driven by the CGRP promoter and targeting NE lung cells spe-
cifically. Both Pten alleles were inactivated in this model. These 
mice developed tumors rapidly with frequent liver metastases 
but the tumor histologies showed somewhat different features 
than the model from the MacPherson laboratory. Mild-modest 
FIGURE 1.  SCLC tumors. A and C, Berns laboratory, (p53/Rb1 double CKO); B and D, Sage laboratory, (p53/Rb/p130 triple 
CKO). A, Whole lung section demonstrating multiple in situ lesions arising in large airways and a few small invasive carcinomas. 
Bar 10 microns. B, SCLC with area of necrosis and Azzopardi effect adjacent to a focus of LCNEC. C, High power view of SCLC 
morphology. D, Combined SCLC carcinoma, with focal areas of poorly differentiated NSCLC. NSCLC, non–small-cell lung carci-
noma; SCLC, small-cell lung carcinoma.
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FIGURE 2.  Metastases from SCLC. In all models examined, the metastatic tumors usually had SCLC morphology irrespective 
of the GEMM or the dominant pulmonary tumor phenotype. A and C, Berns laboratory, (B) Sage laboratory, (D) Jacks labora-
tory (p53/Rb1/Pten triple CKO). A, Extensive mediastinal spread, modest intrapulmonary tumor. B, Intrapulmonary perivascu-
lar lymphatic spread with focal invasion of BV wall. C, Metastasis to mediastinal node. D, Metastases to liver. Horizontal bars 
Distance in microns as indicated. SCLC, small-cell lung carcinoma; GEMM, genetically engineered mouse model; BV, blood 
vessel.
NE cell hyperplasia and NEBs were present in the large bron-
chi. Although most of the in situ lesions were LCNEC, and 
occasionally SCLC, three types of invasive cancers were noted: 
about 60% were LCNEC, 20% SCLC, and 20% NSCLC. 
Heterogeneous expression of CGRP expression was present 
in all three forms of invasive cancers, as well as in the in situ 
lesions. However, the metastases to peribronchial and perivas-
cular lymphatics and to the liver were almost all SCLC.
Pathology of CC10-SV40Tag-
Ascl1 Model GEMM
In this model, there is constitutive co-expression of 
SV40 large T antigen and Ascl1 under the Scgb1a1 (also 
known as CC10) promoter.30–32 At a relatively young age 
(2–4 months), mice develop extensive acinar adenocarci-
nomas, mainly peripheral, but with some arising in larger 
bronchi (Fig. 5). In addition to the adenocarcinomas, foci of 
NE cell hyperplasia that appeared linear along the epithelium 
were present in the large bronchi. Although the foci of NE 
cell hyperplasia expressed the NE cell markers (Ascl1, Cgrp, 
and Syn) strongly and uniformly, expression in the adenocar-
cinomas was focal, weaker, and heterogeneous. Nkx2.1 was 
also expressed in both the NE cell hyperplasias and in the 
adenocarcinomas.
DISCUSSION
As appropriate GEMMs are a key component for the 
understanding of SCLC and other high-grade NE lung car-
cinomas, we undertook a detailed pathological review of the 
multiple mouse models currently available to us. We obtained 
these models both from the originating laboratories, as well as 
from other laboratories that had replicated the models. We are 
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aware that several other GEMMs for NE lung cancers are cur-
rently under development or study. However, as these have not 
been described in the literature, we chose not to include them 
in this study even though, in some instances, the originators 
were willing to share them with us.
Early GEMM models were created by ectopic transgene 
expression under the control of lung-specific promoters.33,34 
More advanced GEMMs allow for inducible, tissue-specific 
expression of oncogenes as well as conditional, tissue-spe-
cific deletion of tumor suppressors. We included in our study 
one early model, described more than a decade ago from the 
Linnoila laboratory, as it represented a model for the poorly 
understood and studied NSCLC-NE tumors. In this model, 
lung tumors are generated by constitutive expression of 
Ascl1 in combination with SV40 T antigen under the sec-
retoglobin1a1 gene promoter. The other four models were 
more advanced models that utilized or modified the origi-
nal double knockout concept from the Berns laboratory. As 
Berns postulated, because biallelic inactivation of TP53 and 
RB1 genes are near universal in human SCLC, knocking out 
these two genes in mouse lung epithelial cells would result in 
SCLC-like tumors. However, in this GEMM, the latent period 
for tumor development was long (about 12 months). Human 
SCLC tumors almost always occur in patients having lengthy 
and extensive smoke exposure histories, and are accompanied 
by numerous molecular changes.11,12,35 By contrast, GEMMs 
for NE lung cancers are not exposed to tobacco carcinogens, 
and require spontaneous development of further genetic 
changes for tumor development including frequent amplifica-
tion of the Nfib and L-Myc genes.36,37 The secondary changes 
in the GEMM model for SCLC from the Jacks lab included 
alterations in DNA copy number and complex genomic rear-
rangements but a relatively low somatic point mutation fre-
quency in the absence of tobacco mutagens.17,18 Alterations 
targeting the tumor suppressor Pten occurred in the majority 
of murine SCLC studied. The relatively lengthy time required 
FIGURE 3.  LCNECs. A and B, Johnson laboratory; (C and D) Sage laboratory (both laboratories used the same p53/Rb1/p130 
triple CKO). A, Intrabronchial in situ lesion with underlying invasive component. B, A lesion similar to the one illustrated in A, 
CGRP immunostain. Strong cytoplasmic expression of the NE cell product CGRP in both the in situ and invasive tumor com-
ponents. C, High power view of LCNEC morphology. D, Both LCNEC (left field) to SCLC (right field) morphologies are present 
within a single lesion. SCLC, small-cell lung carcinoma; NE, neuroendocrine; LCNEC, large-cell NE cell carcinoma.
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for these secondary changes to occur results in long latent 
periods for tumor development. The Sage, MacPherson, and 
Jacks laboratories, in efforts to shorten the latent time, uti-
lized triple knockout GEMMs, modifying the original Rb/
p53 double knockout model with the additional inactivation 
of a third tumor suppressor gene. Further refinements include 
Cre activation in all exposed lung cells or promoter activa-
tion in specific lineage subpopulations such as pulmonary NE 
cells. A further confounding factor is the inactivation of one or 
both alleles of one or more of the utilized genes. As described 
herein, these additional alterations affected the pathological 
features of the resulting tumors.
The five models studied shared some pathological fea-
tures, although there were also individual features character-
izing each GEMM. Most tumors arising in the Rb/p53 Berns 
laboratory double knockout model closely resembled human 
SCLC, although some minor cytological differences were 
noted. A minor subpopulation of LCNEC was present in most 
mice, either as individual foci or admixed with the SCLC foci, 
with transition areas. About 10% of the tumors appeared to 
be NSCLC, especially adenocarcinoma, and lacked NE cell 
differentiation. The original report from the Berns lab indi-
cated that biallelic inactivation of the Rb1 gene was essen-
tial for SCLC tumors in the double knockout model, and that 
NSCLC may arise in the absence of biallelic inactivation.15,38 
These NSCLC tumors lacked NE cell differentiation. Another 
interesting feature was the presence of multiple, often large, 
nodular, and protruding foci of in situ NE cell carcinoma. 
Occasional foci of basally located NE cell hyperplasia or 
increased numbers of NEBs were noted, usually distinct from 
the carcinoma in situ foci. NEBs represent basally located 
focal collections of NE cells in the respiratory epithelium.39 
As premalignant or preinvasive lesions are very seldom rec-
ognized in human SCLC tumors, the GEMMs provide unique 
FIGURE 4.  NSCLC tumors. A and B, Johnson laboratory; (C and D) MacPherson laboratory (p53/Rb1/PTEN triple CKO). A and 
B, Adjacent LCNEC (left field) and NSCLC (right field) tumors in the p130 triple knockout model. CGRP immunostaining (B) is 
limited to the LCNEC tumor and an adjacent NEB within a bronchus separating the two tumors. C and D, In situ SCLC and adja-
cent invasive NSCLC-NE arising in a Ptenlox/+ triple knockout mouse. CGRP immunostaining (D) demonstrates that the NE cell 
marker expression is limited to the in situ SCLC component and to a NEB in the same bronchus. NSCLC, non–small-cell lung 
carcinoma; SCLC, small-cell lung carcinoma; NE, neuroendocrine; LCNEC, large-cell NE cell carcinoma; NSCLC-NE, NSCLC with 
NE features; NEB, neuroepithelial body.
561Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015 Neuroendocrine Carcinomas of the Lung
models to study the multistage pathogenesis of these tumors. 
We, and others, have suggested that lung carcinomas may arise 
from the central or peripheral compartments of the lung, with 
most squamous cell and SCLC carcinomas arising from the 
former, and most adenocarcinomas arising from the latter.40 
The in situ findings from the GEMMs confirm the central ori-
gin of most SCLC and LCNEC tumors. This is consistent with 
the findings of Sutherland et al.41 that most SCLC tumors arise 
from centrally located NE cells, whereas occasional tumors 
may also arise from peripherally located SPC positive cells.
The Rb/p53/p130 triple knockout model from the Sage 
laboratory had LCNEC as the most prominent of the in situ 
and early invasive lesions, with the SCLC component becom-
ing more prominent when mice were sacrificed at a later time 
point. However, SCLC formed the majority of the metastatic 
lesions. There appeared to be plasticity between the two com-
ponents, with individual tumors expressing both phenotypes 
with transitional zones where the demarcation was not clear. 
Thus, addition of p130 knockout to the original Berns double-
knockout model resulted in shorter latent periods, but was 
accompanied by alterations of the major tumor cell phenotype 
that altered with time to sacrifice. At all time points, SCLC 
was the predominant component of metastases to lymph node, 
mediastinum, or liver. These observations suggest the close 
relation and inter-relation of SCLC and LCNEC. Although 
the SCLC component was slower to develop, perhaps because 
more secondary genetic changes were needed for its develop-
ment, it was the predominant phenotype present in metastases 
of all the GEMM models studied.
The Rb/p53/Pten triple from the MacPherson labora-
tory (with mono- or biallelic inactivation of Pten added to the 
original double knockout model)17 had the most complex and 
varied pathology of the models studied. The resultant tumors 
had two major phenotypes: Centrally arising SCLC tumors 
and multiple peripherally arising NSCLC, usually adenocar-
cinomas, with intra- and inter-tumor heterogeneity of NE 
FIGURE 5.  NSCLCs with expression of NE cell markers (NSCLC-NE). A and B, MacPherson Laboratory; (C and D) Linnoila 
laboratory (SV40/ASCL1 driven by CC10 promoter). A, Adenocarcinoma. B, Same tumor as A immunostained for CGRP expres-
sion. C and D, Poorly differentiated NSCLC immunostained for Cgrp (C) or Ascl1 (D). There is focal and variable NE marker 
expression in the tumor. Immunostaining of the foci of NE cell hyperplasia in adjacent bronchi show more intense and uniform 
expression of Ascl1. NSCLC, non–small-cell lung carcinoma; NE, neuroendocrine; NSCLC-NE, NSCLC with NE features.
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marker expression. Although the pathological description in 
the original report of this model suggested major differences 
between the mono- and biallelic Pten inactivated tumors, we 
interpret them as being part of a spectrum, with the SCLC-like 
component being dominant in the monoallelic (heterozygous) 
tumors and the NSCLC-NE tumors dominant in the biallelic 
model. One possible explanation is that the short latent period 
for the development of the extensive NSCLC component in 
the biallelic model resulted in death of the mice before the 
SCLC-like component had time to fully develop.
The triple Rb/p53/Pten triple knockout model from the 
MacPherson laboratory targeted all available lung cells using 
Ad-CMV-Cre, whereas the similar model from the Jacks lab 
targeted NE cells using Ad-CGRP-Cre. Perhaps as a result, the 
tumors from the Jacks laboratory demonstrated a mixture of 
LCNEC, SCLC, and NSCLC, whereas the equivalent model 
from the MacPherson laboratory had NSCLC with varying 
expression of NE features as a prominent component.
While the Rb/p53/Pten triple knockout model resulted 
in NSCLC-NE tumors, the constitutive SV40/Ascl1 model 
from the Linnoila laboratory also induced NSCLC-NE 
tumors, but without the prominent SCLC-like component 
seen in the Rb/p53/Ptenlox/+ model. In both SV40/Ascl1 and 
Rb/p53/Ptenlox/lox models, the NSCLC-NE tumors demon-
strated considerable intra and inter-tumor heterogeneity of 
NE cell markers. NE marker expression was less intense 
than in SCLC or LCNEC components of the Rb/p53 double 
knockout or Rb/p53/p130 triple knockout models. It is of 
interest to point out the contrasting features of the GEMMs 
for the NE carcinoma models as summarized in this report, 
and those of the many GEMM models for NSCLC (Table 3). 
Most NSCLC GEMMs arise peripherally and are character-
ized by intense hyperplastic lesions and adenoma formation, 
with foci of true invasive carcinoma and metastases occur-
ring occasionally and relatively late in the disease process.42,43 
By contrast, the GEMMs for NE carcinomas have relatively 
long latent periods, with the exception of the SV40 driven 
constitutive model from Linnoila laboratory, arise from the 
central compartment, hyperplastic foci are rare, adenomas 
are not seen, and invasive carcinomas and metastatic lesions 
are frequent.42–44
Metastatic lesions were present in all the models for 
which metastatic lesions were available for examination. 
These were most frequent and extensive in the Berns labo-
ratory model, where mice were sacrificed late, often when 
symptomatic. The extent and pattern of metastatic spread, 
sometimes in the presence of modest intrapulmonary tumor 
load, were highly reminiscent of human SCLC—perivascular 
and peribronchial spread, large mediastinal node involve-
ment, frequent and multiple liver metastases. As previously 
mentioned, most metastases in all the models had SCLC cells 
as the principal or sole component, whether or not this was 
the dominant tumor cell component in the intrapulmonary 
tumors.
GEMMs for NE carcinomas of the lung present a unique 
set of models for the study of an important human disease for 
which human tissues are seldom available. The pathological 
features of the four GEMMs that form the basis of this report 
all share some features, but also have individual characteris-
tics. They represent the entire spectrum of high-grade NE car-
cinomas of the lung including LCNEC. Although the original 
double knockout model from the Berns laboratory showed the 
greatest resemblance to human SCLC, many tumors also dem-
onstrated features of LCNEC. These two NE cell components 
often showed mixed patterns in individual tumors, with tran-
sitional features from one to the other. These findings indicate 
that the distinction between the two main forms of high-grade 
NE lung carcinomas is not absolute but relative, and that 
transitions between them may occur. NSCLC tumors, with or 
without expression of NE cell markers were a prominent fea-
ture of the Rb/p53/Pten triple knockout from the MacPherson 
laboratory and the constitutive SV40/Ascl1 model from the 
Linnoila laboratory.
These models offer a spectrum of pathological pheno-
types ranging from SCLC, LCNEC, NSCLC, and the poorly 
understood NSCLC-NE tumors. In most cases, the widely 
metastatic pattern of the conditional models closely resembles 
the pattern of spread of human SCLC. It appears that multiple 
TABLE 3.  Short Summary of the Main Pathological Features of the Main GEMM Models for NE and NSCLC Lung Carcinomas
Feature GEMM Models for NE Lung Carcinomas GEMM Models for NSCLC
Major driver mutation(s) Inactivation of TTp53 and Rb1 (+/- others) Activation of KRAS, EGFR, or other genes
Invasive tumors Frequent Occasionala
Latent time to tumor induction Relatively long (months) Relatively long (months)a
Site of origin Predominantly from central compartment Predominantly from peripheral compartment
Predominant tumor type(s) SCLC, LCNEC, occasional NSCLC NSCLC, usually adenocarcinoma
Hyperplasia Nodular and linear NE cell foci in bronchi Extensive hyperplasia of peripheral airways
Adenoma formation Rare/absent Frequent
Carcinoma in situ Frequent Occasional
Metastatic lesions Frequent, usually of SCLC component Rare
Nb: As multiple GEMMs exist for both NE and NSCLC carcinomas, the above table reflects composite features that may not apply fully to all individual models.33 The NSCLC 
GEMMs include mainly models for adenocarcinomas, as the recently developed GEMMs for squamous cell carcinomas have not been fully characterized to date.33,46
aAlthough extensive preneoplastic lesions appear relatively early in most GEMMs for NSCLC, true invasive cancers appear late during multistage pathogenesis and they rarely 
metastasize.
NSCLC, non–small-cell lung carcinoma; SCLC, small-cell lung carcinoma; GEMM, genetically engineered mouse model; NE, neuroendocrine; LCNEC, large-cell NE cell 
carcinoma.
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factors can influence the resultant tumor phenotypes including 
introduced genetic changes, targeting of niche subpopulations 
such as NE cells, mono- or biallelic inactivation of genes, and 
time period to sacrifice after Cre activation.
Böck et al.45 has recently described the development 
and advancement of mouse models for human cancer. They 
hierarchically cluster mouse models of cancer into five 
stages of development and sophistication. The fifth stage, 
largely futuristic, includes earlier stage models mimicking 
metastatic progression, with metastasis becoming rate lim-
iting for tumor growth. In our opinion, the conditional NE 
carcinoma models fulfill these criteria, and thus represent 
one of the most advanced of the currently available mouse 
models for cancer.
CONCLUSIONS
GEMMs offer appropriate and potentially useful models 
for the study of the multistage development, invasion, metas-
tases, and therapy of the entire spectrum of human high-grade 
NE lung carcinomas. A detailed understanding of the pathol-
ogy and biology of the individual GEMM models for NE car-
cinomas is essential for the selection of the most appropriate 
model for future studies.
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